TY - JOUR
T1 - Expression of the MAGE gene family in human gastric carcinoma
AU - Li, Jian
AU - Yang, Yi
AU - Fujie, Tatsuo
AU - Tanaka, Fumiaki
AU - Mimori, Koshi
AU - Haraguchi, Masaru
AU - Ueo, Hiroaki
AU - Mori, Masaki
AU - Akiyoshi, Tsuyoshi
PY - 1997/9/1
Y1 - 1997/9/1
N2 - MAGE genes code tumour antigens that are recognized by cytolytic T lymphocytes and have been shown to be expressed in various malignant tumors. However, there is still little information on the expression of the MAGE gene family except for reports of MAGE-1 and -3. In this study, we therefore investigated the expression of MAGE-4, -6, -8, -9, -10, -11 and -12, as well as MAGE-1, -2 and -3 in both cell lines and surgical samples of gastric carcinoma, using reverse transcription PCR. Of the investigated 11 cell lines, MAGE-4, -6, -8, -9, -10, -11 and -12 were detected in 8 (73%), 6 (55%), 2 (18%), 59 (44%), 6 (55%), 4 (36%) , and 7 (64%), respectively. No expression of these genes was seen in any of the 54 samples of normal gastric tissue. In contract the tumor tissue samples were found to express MAGE-4, -6, -8, -9, -10, -11, and -12 in 18 (33%), 13 (24%), 6 (11%), 10 (19%), 5 (9%), 13 (24%), and 10 (19%), respectively. Forty-four (82%) of 54 gastric tumors expressed at least one of these genes. No significant correlation was observed between the expression of MAGE genes and any specific clinicopathological factors. These results may hopefully prove to be useful in developing strategies for tumor-specific immunotherapy of gastric carcinoma using MAGE gene products.
AB - MAGE genes code tumour antigens that are recognized by cytolytic T lymphocytes and have been shown to be expressed in various malignant tumors. However, there is still little information on the expression of the MAGE gene family except for reports of MAGE-1 and -3. In this study, we therefore investigated the expression of MAGE-4, -6, -8, -9, -10, -11 and -12, as well as MAGE-1, -2 and -3 in both cell lines and surgical samples of gastric carcinoma, using reverse transcription PCR. Of the investigated 11 cell lines, MAGE-4, -6, -8, -9, -10, -11 and -12 were detected in 8 (73%), 6 (55%), 2 (18%), 59 (44%), 6 (55%), 4 (36%) , and 7 (64%), respectively. No expression of these genes was seen in any of the 54 samples of normal gastric tissue. In contract the tumor tissue samples were found to express MAGE-4, -6, -8, -9, -10, -11, and -12 in 18 (33%), 13 (24%), 6 (11%), 10 (19%), 5 (9%), 13 (24%), and 10 (19%), respectively. Forty-four (82%) of 54 gastric tumors expressed at least one of these genes. No significant correlation was observed between the expression of MAGE genes and any specific clinicopathological factors. These results may hopefully prove to be useful in developing strategies for tumor-specific immunotherapy of gastric carcinoma using MAGE gene products.
UR - http://www.scopus.com/inward/record.url?scp=0030807727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030807727&partnerID=8YFLogxK
M3 - Article
C2 - 9413202
AN - SCOPUS:0030807727
VL - 17
SP - 3559
EP - 3563
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 5 A
ER -
